drugset
drugset / Trial / NCT03428984

Study in Adult Subjects Undergoing Posterolateral Thoracotomy

NCT03428984 ↗

Phase 1 Terminated 5 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary Objective: To characterize the pharmacokinetic (PK) profile of EXPAREL when administered as a posterior intercostal nerve block. Secondary Objective: To assess the safety and tolerability of EXPAREL in this surgical model.

Timeline

Start
2018-05-03
Primary completion
2018-09-28
Completion
2018-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Other

Indications

No indication recorded.